Zhejiang Garden Biopharmaceutical Co.,Ltd.

SZSE:300401 Stock Report

Market Cap: CN¥8.5b

Zhejiang Garden BiopharmaceuticalLtd Future Growth

Future criteria checks 5/6

Zhejiang Garden BiopharmaceuticalLtd is forecast to grow earnings and revenue by 41.5% and 32.2% per annum respectively while EPS is expected to grow by 42.2% per annum.

Key information

41.5%

Earnings growth rate

42.23%

EPS growth rate

Pharmaceuticals earnings growth18.1%
Revenue growth rate32.2%
Future return on equityn/a
Analyst coverage

Low

Last updated27 Jan 2026

Recent future growth updates

Recent updates

Analysis Article • Jan 06

Fewer Investors Than Expected Jumping On Zhejiang Garden Biopharmaceutical Co.,Ltd. (SZSE:300401)

With a price-to-earnings (or "P/E") ratio of 27.2x Zhejiang Garden Biopharmaceutical Co.,Ltd. ( SZSE:300401 ) may be...
Analysis Article • Oct 24

Zhejiang Garden BiopharmaceuticalLtd's (SZSE:300401) Profits May Not Reveal Underlying Issues

Zhejiang Garden Biopharmaceutical Co.,Ltd.'s ( SZSE:300401 ) robust recent earnings didn't do much to move the stock...
Analysis Article • Sep 29

Zhejiang Garden BiopharmaceuticalLtd (SZSE:300401) Has A Somewhat Strained Balance Sheet

Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...
Analysis Article • Sep 08

Zhejiang Garden Biopharmaceutical Co.,Ltd.'s (SZSE:300401) Stock Retreats 26% But Earnings Haven't Escaped The Attention Of Investors

Zhejiang Garden Biopharmaceutical Co.,Ltd. ( SZSE:300401 ) shares have retraced a considerable 26% in the last month...
Analysis Article • Jun 30

Why Investors Shouldn't Be Surprised By Zhejiang Garden Biopharmaceutical Co.,Ltd.'s (SZSE:300401) 27% Share Price Surge

Zhejiang Garden Biopharmaceutical Co.,Ltd. ( SZSE:300401 ) shares have continued their recent momentum with a 27% gain...
Analysis Article • May 31

Is Zhejiang Garden BiopharmaceuticalLtd (SZSE:300401) A Risky Investment?

Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...
Analysis Article • May 06

Subdued Growth No Barrier To Zhejiang Garden Biopharmaceutical Co.,Ltd. (SZSE:300401) With Shares Advancing 27%

Despite an already strong run, Zhejiang Garden Biopharmaceutical Co.,Ltd. ( SZSE:300401 ) shares have been powering on...
Analysis Article • Apr 22

Why Zhejiang Garden BiopharmaceuticalLtd's (SZSE:300401) Shaky Earnings Are Just The Beginning Of Its Problems

Despite Zhejiang Garden Biopharmaceutical Co.,Ltd.'s ( SZSE:300401 ) recent earnings report having lackluster headline...

Earnings and Revenue Growth Forecasts

SZSE:300401 - Analysts future estimates and past financials data (CNY Millions)
DateRevenueEarningsFree Cash FlowCash from OpAvg. No. Analysts
12/31/20272,134568N/A5201
12/31/20261,674434N/A2991
3/31/20261,188259197530N/A
12/31/20251,237305113475N/A
9/30/20251,241302103540N/A
6/30/20251,27832975555N/A
3/31/20251,239314-12499N/A
12/31/20241,243309-14466N/A
9/30/20241,134285-88328N/A
6/30/20241,038217-140210N/A
3/31/20241,108232-133131N/A
12/31/20231,095192-85160N/A
9/30/20231,237179-134109N/A
6/30/20231,274204-83190N/A
3/31/20231,348284-45271N/A
1/1/20231,418384-3377N/A
9/30/20221,427466-62449N/A
6/30/20221,38546124677N/A
3/31/20221,329543-83660N/A
1/1/20221,117484-203512N/A
9/30/2021937409-77591N/A
6/30/2021847420-223385N/A
3/31/2021699293-139455N/A
12/31/2020659263-166427N/A
9/30/2020630261-341311N/A
6/30/2020645277-218366N/A
3/31/2020617276-264275N/A
12/31/2019718344N/A367N/A
9/30/2019763392N/A410N/A
6/30/2019758384N/A322N/A
3/31/2019661315N/A318N/A
1/1/2019660307N/A253N/A
9/30/2018585252N/A193N/A
6/30/2018508208N/A224N/A
3/31/2018569232N/A229N/A
1/1/2018420130N/A148N/A
9/30/2017416120N/A117N/A
6/30/2017403103N/A98N/A
3/31/201735560N/A75N/A
12/31/201632944N/A49N/A
9/30/201627229N/A65N/A
6/30/201623917N/A26N/A
3/31/201617810N/A22N/A
12/31/201515112N/A43N/A
9/30/201515222N/A42N/A
6/30/201515833N/A12N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: 300401's forecast earnings growth (41.5% per year) is above the savings rate (2.4%).

Earnings vs Market: 300401's earnings (41.5% per year) are forecast to grow faster than the CN market (27% per year).

High Growth Earnings: 300401's earnings are expected to grow significantly over the next 3 years.

Revenue vs Market: 300401's revenue (32.2% per year) is forecast to grow faster than the CN market (16.5% per year).

High Growth Revenue: 300401's revenue (32.2% per year) is forecast to grow faster than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: Insufficient data to determine if 300401's Return on Equity is forecast to be high in 3 years time

Discover growth companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2026/06/16 17:03
End of Day Share Price 2026/06/16 00:00
Earnings2026/03/31
Annual Earnings2025/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Zhejiang Garden Biopharmaceutical Co.,Ltd. is covered by 1 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Zhe WangCitic Securities Co., Ltd.